The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial

Louise B Glenthøj, Birgitte Fagerlund, Lasse Randers, Carsten R Hjorthøj, Christina Wenneberg, Kristine Krakauer, Astrid Vosgerau, Christian Gluud, Alice Medalia, David L Roberts, Merete Nordentoft, Louise B Glenthøj, Birgitte Fagerlund, Lasse Randers, Carsten R Hjorthøj, Christina Wenneberg, Kristine Krakauer, Astrid Vosgerau, Christian Gluud, Alice Medalia, David L Roberts, Merete Nordentoft

Abstract

Background: Cognitive deficits are a distinct feature among people at ultra-high risk (UHR) for psychosis and pose a barrier to functional recovery. Insufficient evidence exists on how to ameliorate these cognitive deficits in patients at UHR for psychosis and hence improve daily living and quality of life. The aim of the trial is to investigate whether cognitive remediation can improve cognitive and psychosocial function in patients at UHR for psychosis.

Methods: The FOCUS trial (Function and Overall Cognition in Ultra-high risk States) is a randomised, parallel group, observer-blinded clinical trial enrolling 126 patients meeting the standardised criteria of being at UHR for psychosis. Patients are recruited from psychiatric in- and outpatient facilities in the Copenhagen catchment area. Patients are randomised to one of the two treatment arms: cognitive remediation plus standard treatment versus standard treatment. The cognitive remediation consists of 24 weekly group-based and manualised sessions targeting neurocognition and social cognition. In addition to the group sessions, the patients will be offered 12 individual sessions aiming at maximising the transfer of the effects of the cognitive training to their everyday lives. Follow-up assessments will be conducted at 6 and 12 months after randomisation. The primary outcome is the composite score on the Brief Assessment of Cognition in Schizophrenia at cessation of treatment after 6 months. Secondary outcomes are social and daily functioning, psychosis-like symptoms, negative symptomatology, and depressive symptomatology as measured with the Personal and Social Performance Scale, Brief Psychiatric Rating Scale-Expanded Version, Scale for the Assessment of Negative Symptoms, and the Montgomery-Åsberg Depression Rating Scale.

Discussion: This is the first trial to evaluate the effects of neurocognitive and social cognitive remediation in UHR patients. The FOCUS trial results will provide evidence on the effect of targeted and comprehensive cognitive rehabilitation on cognition, daily living, and symptomatology as well as long-term outcome in preventing transition to psychosis in UHR patients.

Trial registration: ClinicalTrials.gov NCT 02098408 . Date of registration 18 March 2014.

Trial registration: ClinicalTrials.gov NCT02098408.

Figures

Figure 1
Figure 1
Flowchart of the FOCUS trial.

References

    1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76. doi: 10.1093/epirev/mxn001.
    1. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70:107–20. doi: 10.1001/jamapsychiatry.2013.269.
    1. van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res. 2013;149:56–62. doi: 10.1016/j.schres.2013.07.004.
    1. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921–8. doi: 10.1001/archpsyc.59.10.921.
    1. McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry. 2013;74:349–56. doi: 10.4088/JCP.12m07785.
    1. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163:790–9. doi: 10.1176/ajp.2006.163.5.790.
    1. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146–54. doi: 10.1001/archgenpsychiatry.2009.192.
    1. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res. 2006;83:29–40. doi: 10.1016/j.schres.2006.01.002.
    1. Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2012;200:22–9. doi: 10.1192/bjp.bp.109.066357.
    1. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185:291–7. doi: 10.1192/bjp.185.4.291.
    1. Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ. 2012;344:e2233. doi: 10.1136/bmj.e2233.
    1. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125:54–61. doi: 10.1016/j.schres.2010.10.015.
    1. van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RM, et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull. 2012;38:1180–8. doi: 10.1093/schbul/sbs105.
    1. Bellack AS, Gold JM, Buchanan RW. Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. Schizophr Bull. 1999;25:257–74. doi: 10.1093/oxfordjournals.schbul.a033377.
    1. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26:119–36. doi: 10.1093/oxfordjournals.schbul.a033430.
    1. Wykes T, Spaulding WD. Thinking about the future cognitive remediation therapy–what works and could we do better? Schizophr Bull. 2011;37(Suppl 2):S80–90. doi: 10.1093/schbul/sbr064.
    1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–30. doi: 10.1176/ajp.153.3.321.
    1. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007;164:1791–802. doi: 10.1176/appi.ajp.2007.07060906.
    1. Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2011;35:573–88. doi: 10.1016/j.neubiorev.2010.07.001.
    1. Schmidt SJ, Mueller DR, Roder V. Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophr Bull. 2011;37(Suppl 2):S41–54. doi: 10.1093/schbul/sbr079.
    1. Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull. 2008;34:1211–20. doi: 10.1093/schbul/sbm145.
    1. Bartholomeusz CF, Allott K. Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence. Schizophr Res Treat. 2012;2012:815315.
    1. Addington J, Saeedi H, Addington D. Facial affect recognition: a mediator between cognitive and social functioning in psychosis? Schizophr Res. 2006;85:142–50. doi: 10.1016/j.schres.2006.03.028.
    1. Addington J, Saeedi H, Addington D. Influence of social perception and social knowledge on cognitive and social functioning in early psychosis. Br J Psychiatry. 2006;189:373–8. doi: 10.1192/bjp.bp.105.021022.
    1. Horton HK, Silverstein SM. Social cognition as a mediator of cognition and outcome among deaf and hearing people with schizophrenia. Schizophr Res. 2008;105:125–37. doi: 10.1016/j.schres.2008.07.003.
    1. Nienow TM, Docherty NM, Cohen AS, Dinzeo TJ. Attentional dysfunction, social perception, and social competence: what is the nature of the relationship? J Abnorm Psychol. 2006;115:408–17. doi: 10.1037/0021-843X.115.3.408.
    1. Vaskinn A, Sundet K, Friis S, Simonsen C, Birkenaes AB, Jonsdottir H, et al. Emotion perception and learning potential: mediators between neurocognition and social problem-solving in schizophrenia? J Int Neuropsychol Soc. 2008;14:279–88. doi: 10.1017/S1355617708080314.
    1. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull. 2006;32(Suppl 1):S44–63. doi: 10.1093/schbul/sbl029.
    1. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168:472–85. doi: 10.1176/appi.ajp.2010.10060855.
    1. Lewandowski KE, Eack SM, Hogarty SS, Greenwald DP, Keshavan MS. Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder? Schizophr Res. 2011;125:291–4. doi: 10.1016/j.schres.2010.11.017.
    1. Deckersbach T, Nierenberg AA, Kessler R, Lund HG, Ametrano RM, Sachs G, et al. RESEARCH: Cognitive rehabilitation for bipolar disorder: An open trial for employed patients with residual depressive symptoms. CNS Neurosci Ther. 2010;16:298–307. doi: 10.1111/j.1755-5949.2009.00110.x.
    1. Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med. 2011;41:225–41. doi: 10.1017/S0033291710001042.
    1. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry. 2011;45:93–108. doi: 10.3109/00048674.2010.541418.
    1. Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull. 2014;40(4):744–55. doi: 10.1093/schbul/sbt085.
    1. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69:562–71.
    1. Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, et al. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res. 2004;67:115–22. doi: 10.1016/j.schres.2003.08.007.
    1. Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O’Brien M, et al. Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res. 2006;84:100–11. doi: 10.1016/j.schres.2006.02.005.
    1. Brewer WJ, Wood SJ, Phillips LJ, Francey SM, Pantelis C, Yung AR, et al. Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr Bull. 2006;32:538–55. doi: 10.1093/schbul/sbj077.
    1. Thompson AD, Bartholomeusz C, Yung AR. Social cognition deficits and the ‘ultra high risk’ for psychosis population: a review of literature. Early Interv Psychiatry. 2011;5:192–202. doi: 10.1111/j.1751-7893.2011.00275.x.
    1. Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, et al. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res. 2011;132:1–7. doi: 10.1016/j.schres.2011.06.014.
    1. Rauchensteiner S, Kawohl W, Ozgurdal S, Littmann E, Gudlowski Y, Witthaus H, et al. Test-performance after cognitive training in persons at risk mental state of schizophrenia and patients with schizophrenia. Psychiatry Res. 2011;185:334–9. doi: 10.1016/j.psychres.2009.09.003.
    1. Jakobsen J, Gluud C. The necessity of randomized clinical trials. Br J Med Clin Res. 2013;3(3):1453–68.
    1. Harvey PD. What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? J Clin Psychiatry. 2014;75(Suppl 2):34–8. doi: 10.4088/JCP.13065su1.08.
    1. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull. 1996;22:201–22. doi: 10.1093/schbul/22.2.201.
    1. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry. 2005;39:964–71. doi: 10.1080/j.1440-1614.2005.01714.x.
    1. Medalia A, Revheim N, Herlands T. Cognitive remediation for psychological disorders: therapist guide. New York: Oxford: Oxford University Press; 2009.
    1. Medalia A, Freilich B. The neuropsychological education approach to cognitive remediation (NEAR) model: practice principles and outcome studies. Am J Psychiatr Rehabil. 2008;11:2. doi: 10.1080/15487760801963660.
    1. Roberts DL, Penn DL, Combs DR. Social Cognition and Interaction Training SCIT: Treatment Manual. New York: Oxford University Press; In press
    1. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P) Psychiatry Res. 1998;79:163–73. doi: 10.1016/S0165-1781(98)00038-9.
    1. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured clinical interview for DSM-IV axis II personality disorders: SCID-II. Washington, DC: American Psychiatric Press; 1997.
    1. Strauss E, Sherman EMS, Spreen O, Spreen O. A Compendium Of Neuropsychological Tests: Administration, Norms, And Commentary. 3. New York: Oxford University Press; 2006.
    1. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:283–97. doi: 10.1016/j.schres.2003.09.011.
    1. Gioia GA, Kenworthy L, Isquith PK. Executive function in the real world: BRIEF lessons from Mark Ylvisaker. J Head Trauma Rehabil. 2010;25:433–9. doi: 10.1097/HTR.0b013e3181fbc272.
    1. Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The schizophrenia cognition rating scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry. 2006;163:426–32. doi: 10.1176/appi.ajp.163.3.426.
    1. Keefe RS, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) Schizophr Res. 2008;102:108–15. doi: 10.1016/j.schres.2008.03.024.
    1. Levaux MN, Potvin S, Sepehry AA, Sablier J, Mendrek A, Stip E. Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry. 2007;22:104–15. doi: 10.1016/j.eurpsy.2006.11.004.
    1. Lowe C, Rabbitt P. Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia. 1998;36:915–23. doi: 10.1016/S0028-3932(98)00036-0.
    1. Barnett JH, Robbins TW, Leeson VC, Sahakiana BJ, Joyce EM, Blackwell AD. Assessing cognitive function in clinical trials of schizophrenia. Neurosci Biobehav Rev. 2010;34:1161–77. doi: 10.1016/j.neubiorev.2010.01.012.
    1. McDonald S, Flanagan S, Rollins J, Kinch J. TASIT: a new clinical tool for assessing social perception after traumatic brain injury. J Head Trauma Rehabil. 2003;18:219–38. doi: 10.1097/00001199-200305000-00001.
    1. Gibson CM, Penn DL, Prinstein MJ, Perkins DO, Belger A. Social skill and social cognition in adolescents at genetic risk for psychosis. Schizophr Res. 2010;122:179–84. doi: 10.1016/j.schres.2010.04.018.
    1. Kanie A, Hagiya K, Ashida S, Pu S, Kaneko K, Mogami T, Oshima S, Motoya M, Niwa SI, Inagaki A, et al. A new instrument for measuring multiple domains of social cognition: Construct validity of the Social Cognition Screening Questionnaire (Japanese version) Psychiatry Clin Neurosci. 2014;68(9):701–11. doi: 10.1111/pcn.12181.
    1. Bolte S, Poustka F, Constantino JN. Assessing autistic traits: cross-cultural validation of the social responsiveness scale (SRS) Autism Res. 2008;1:354–63. doi: 10.1002/aur.49.
    1. Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res. 2000;97:129–35. doi: 10.1016/S0165-1781(00)00228-6.
    1. Andreasen NC. Scale for the assessment of negative symptoms: SANS. Iowa City, Iowa: Dept. of Psychiatry, College of Medicine, the University of Iowa; 1984.
    1. Andreasen NC, Flaum M, Swayze VW, 2nd, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry. 1990;47:615–21. doi: 10.1001/archpsyc.1990.01810190015002.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9. doi: 10.1192/bjp.134.4.382.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35. doi: 10.1192/bjp.133.5.429.
    1. Guy W. Rockville, MD, US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. 1976. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338) pp. 218–22.
    1. Schultze-Lutter F, Ruhrmann S, Fusar-Poli P, Bechdolf A, Schimmelmann BG, Klosterkotter J. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des. 2012;18:351–7. doi: 10.2174/138161212799316064.
    1. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101:323–9.
    1. Hilsenroth MJ, Ackerman SJ, Blagys MD, Baumann BD, Baity MR, Smith SR. Reliability and Validity of DSM-IV Axis V. Am J Psychiatr. 2000;157:1858–63. doi: 10.1176/appi.ajp.157.11.1858.
    1. Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull. 2007;33:688–702. doi: 10.1093/schbul/sbm029.
    1. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:470–84. doi: 10.1093/schbul/8.3.470.
    1. World Health Organisation ASSIST Working Group The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002;97:1183–1194. doi: 10.1046/j.1360-0443.2002.00185.x.
    1. Heinrichs DW, Hanlon TE, Carpenter WTJR. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388–98. doi: 10.1093/schbul/10.3.388.
    1. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2:197–207. doi: 10.1016/0149-7189(79)90094-6.
    1. Klingberg S, Herrlich J, Wiedemann G, Wolwer W, Meisner C, Engel C, et al. Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. J Nerv Ment Dis. 2012;200:569–76. doi: 10.1097/NMD.0b013e31825bfa1d.
    1. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry. 2005;162:71–8. doi: 10.1176/appi.ajp.162.1.71.
    1. Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, et al. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? Psychol Med. 2010;40:1599–606. doi: 10.1017/S0033291710000048.
    1. Frommann I, Pukrop R, Brinkmeyer J, Bechdolf A, Ruhrmann S, Berning J, et al. Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early–and additional memory dysfunction in the late–prodromal state. Schizophr Bull. 2011;37:861–73. doi: 10.1093/schbul/sbp155.
    1. Eastvold AD, Heaton RK, Cadenhead KS. Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr Res. 2007;93:266–77. doi: 10.1016/j.schres.2007.03.013.
    1. Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161:213–24. doi: 10.1016/j.psychres.2007.11.012.
    1. Ballerini A, Boccalon R, Boncompagni G, Casacchia M, Margari F, Minervini L, et al. An observational study in psychiatric acute patients admitted to General Hospital Psychiatric Wards in Italy. Ann Gen Psychiatry. 2007;6:2. doi: 10.1186/1744-859X-6-2.
    1. Lepping P, Sambhi RS, Whittington R, Lane S, Poole R. Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry. 2011;198:341–5. doi: 10.1192/bjp.bp.109.075366.
    1. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med. 2012;157:429–38. doi: 10.7326/0003-4819-157-6-201209180-00537.
    1. Eack SM, Greenwald DP, Hogarty SS, Cooley SJ, DiBarry AL, Montrose DM, et al. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv. 2009;60:1468–76. doi: 10.1176/ps.2009.60.11.1468.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel